Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 326 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hemoglobin Clear all

Conditions: Sickle Cell Anemia, Sickle Cell Disease, Hemoglobin Disorder
Interventions: Metformin, Questionnaires; Drug · Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 10 Years to 60 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Anemia, Lung Cancer
Interventions: methoxy polyethylene glycol epoetin beta; Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Anaemia
Interventions: GSK1278863; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Lakewood, Colorado • Minneapolis, Minnesota

Conditions: Carbon Monoxide Poisoning
Interventions: Pulse Oximeter; Device
Lead sponsor: Nonin Medical, Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Timeline: 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Anemia, Diamond-Blackfan
Interventions: Eltrombopag; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Determine Validity of Concept of Using Hemoglobin Dilution to Assess/Measure Blood Volume.
Interventions: Blood Volume Dilution; Drug
Lead sponsor: Kai Schoenhage; Other
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin S Disease, Sickling Disorder Due to Hemoglobin S
Interventions: HQK-1001, Placebo; Drug
Lead sponsor: HemaQuest Pharmaceuticals Inc.; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 11
States / cities: Mobile, Alabama • Oakland, California • Washington D.C., District of Columbia + 7 more

Conditions: Anemia, Healthy, Pediatric ALL
Interventions: Rad-67 Pulse oximeter; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 1 Month and older
Enrollment: 447 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 7
States / cities: Burbank, California • Irvine, California • Lake Forest, California + 3 more

Conditions: Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions: peginesatide, Darbepoetin alfa; Drug
Lead sponsor: Affymax; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 42
States / cities: Phoenix, Arizona • Fayetteville, Arkansas • Fountain Valley, California + 38 more

Conditions: Elective Cardiac Surgery
Interventions: CytoSorb; Device
Lead sponsor: CytoSorbents, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 20
States / cities: New Haven, Connecticut • Chicago, Illinois • Indianapolis, Indiana + 16 more

Conditions: Breast Cancer, Neoplasm Metastasis
Interventions: Standard supportive care (packed RBC transfusion), epoetin alfa + packed RBC transfusion; Other · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 2,098 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 14
States / cities: Anaheim, California • Gainesville, Florida • Miami, Florida + 11 more

Conditions: Sickle Cell Anemia
Interventions: Hydroxyurea, L-Arginine, Sildenafil; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 16 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anemia, Renal Diseases
Interventions: epoetin alfa; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 66
States / cities: Chula Vista, California • Fountain Valley, California • Los Angeles, California + 63 more

Conditions: Anemia
Interventions: Masimo Rad-67 Pulse Oximeter; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 1 Month and older
Enrollment: 368 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Irvine, California

Conditions: Sickle Cell Disease
Interventions: single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a; Biological
Lead sponsor: David Williams; Other
Eligibility: 3 Years to 40 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Los Angeles, California • Boston, Massachusetts

Conditions: Post Partum Hemorrhage, Anemia of Pregnancy
Interventions: Masimo Root Radical 7 Pulse CO-Oximeter, HemoCue Hb 801; Device
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Falls Church, Virginia

Conditions: Hemoglobinuria, Paroxysmal
Interventions: Eculizumab; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anemia, Sickle Cell
Interventions: Glutamine, Placebo; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years to 18 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Type 2 Diabetes
Interventions: FAMS 2.0, Print Materials; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes Mellitus
Interventions: Diabetes Outcome; Diagnostic Test
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 80 Years
Enrollment: 34,121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Beta Thalassemia
Interventions: 5-Azacytidine; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Iron Deficiency
Interventions: Ferrous gluconate- 19 mg, Ferrous gluconate- 38 mg, Letter Group- Information Provided, Letter - No Information Provided, Placebo; Dietary Supplement · Other
Lead sponsor: Westat; Other
Eligibility: 18 Years to 100 Years
Enrollment: 702 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 4
States / cities: Farmington, Connecticut • Rockville, Maryland • Pittsburgh, Pennsylvania + 1 more

Conditions: Hemoglobins, Diagnostic Tests
Interventions: MyChart message; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 2,403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Bleeding, Acute Blood Loss Anemia
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Charlotte, North Carolina

Search by objective public record fields.

Fetal Hemoglobin Induction Treatment Metformin

Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis

Dysfunctional Hemoglobin Pulse Oximetry

Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag

Calculating Blood Volume by Dilution of Hemoglobin - Pilot Study

Effects of HQK-1001 in Patients With Sickle Cell Disease

Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation

Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis

CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia

PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients

Spot-Check Noninvasive Pulse CO-Oximeter Validation

Gene Transfer for Sickle Cell Disease

Hemoglobin Testing in Pregnant Patients

Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria

Trial of Oral Glutamine in Patients With Sickle Cell Anemia

Mobile Phone Support for Adults and Support Persons to Live Well With Diabetes

Walnut Consumption and Diabetes Risk

5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia

Strategies to Reduce Iron Deficiency

Electronic Triggers: Messaging After A1C EHR Alert

Continuous Hemoglobin Monitoring: Detection of Acute Blood Loss - Accurate, Timely and Cost-effective